<DOC>
	<DOCNO>NCT00590694</DOCNO>
	<brief_summary>Patients neovascular Age-related macular degeneration ( AMD ) particular feature pigment epithelial detachment ( PEDs ) study Phase III trial ranibizumab ( Lucentis ) . The PrONTO study first ranibizumab study enroll patient treat ranibizumab fluid within layer retina absent , entire PED absent . This study hypothesize may difference benefit patient treat retinal edema go retinal edema PED go .</brief_summary>
	<brief_title>Lucentis Age-related Macular Degeneration Pigment Epithelial Detachments</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Neovascular agerelated macular degeneration patient age 50 Presence pigment epithelial detachment optical coherence tomography Initial recurrent disease Previous treatment allow Visual acuity Snellen 20/40 20/400 More three previous treatment PDT radiation/laser therapy Previous vitrectomy AMD surgical intervention Severe scar severe concurrent ocular disease ( uncontrolled glaucoma ) Patients eligible study randomize one two group . Group 1 receives injection ranibizumab retinal edema resolve . Group 2 receive ranibizumab injection retinal edema PED resolve . Study duration one year visit per month .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>ranibizumab</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Pigment Epithelial Detachment</keyword>
	<keyword>Macular Degeneration</keyword>
	<keyword>PrONTO</keyword>
</DOC>